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Abstract 
Objectives 
Chronic kidney disease (CKD) registries have been used for more than half a century. Iran lacks a comprehensive 
registry to capture data of all CKD patients for an informed care planning and policy making. We aimed to identify 
the objectives and possible challenges for developing a CKD registry and also to define its minimum data set (MDS) 
in our healthcare context. 
Methods 
This was a mixed-method study conducted in Iran from fall 2016 till summer 2017. The qualitative part included 
document analysis and 26 semi-structured interviews with 17 clinicians and managers involved in CKD care. This 
data was analyzed using the "grounded theory". Then, a modified Delphi survey was conducted. Percentages and 
mode values were used for analysis. 
Results 
Our participants' leading interest in a CKD registry was centered on providing a coordinated, qualitative care for all 
CKD stages with particular emphasis to capture events and monitor trends for patients in earlier stages. They 
highlighted the required financial, technical and human resources as main challenges for a smooth registry 
implementation. Furthermore, a clinically oriented MDS comprising of 168 elements (with a majority having more 
than 90% agreement with mode 2) was extracted. It mainly collects demographics, medical history, encounter 
sessions, diagnostic examinations, medications, vaccinations and mortality data. 
Conclusions 
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We reported the initiatory steps taken to establish a CKD registry in an Iranian healthcare context. We focused on 
the information needs and priorities of our main stakeholders and based our intended registry on addressing those 
needs. We hope this approach will facilitate its endorsement and advance the efforts for a sustainable, qualitative 
CKD care. 
 
Keywords: chronic kidney disease, CKD, registry, minimum data set, mixed method, nephrology, chronic renal 
failure, Iran 
Funding: This study was supported financially by Urmia University of Medical Sciences. 
 
1. Introduction 
Chronic kidney disease (CKD) is one of the leading global health problems due to its increasing prevalence and 
associated complications (1). According to a recent systematic review and meta-analysis, the prevalence of CKD has 
been estimated between 11% to 13% worldwide (2). This review highlighted that information on earlier CKD stages 
is still limited despite a higher prevalence. This is of particular concern in developing countries (3). In Iran, different 
studies have provided varying estimates of the disease in adults ranging from 12.6% to 23.7% (4-6). In a study of 
Iranian children, a higher prevalence of CKD was found compared to western countries (7). Adding to this existing 
CKD burden is a growing trend in coming years, which has been predicted in a population based modeling study 
(8). Still, many aspects of CKD care are poorly understood due to limitations in existing data. For example, it is not 
completely clear how care is accessible for different groups with regards to gender, ethnicity and socioeconomic 
status or how progressive the disease is across different regions of the country. To be able to keep up with the 
growing CKD trend, accurate and up to date patient data is required in all stages for informed policy making and 
management planning, as acknowledged by scholars in the field (9).  
Disease registries have a great potential to provide reliable observational data for a specific group of patients (10). 
Their implementations have been associated mostly with a positive impact on healthcare processes and outcomes 
(11). Furthermore, such registries can potentially become an efficient policymaking tool (12). The oldest renal 
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registry was founded in Europe in 1964 (13). In a recent systematic review, 144 renal registries were identified 
worldwide with varying aims, structures, and CKD patients targeted (14). Noteworthy is that a majority of these 
registries were based in developed countries and focused on end stage renal diseases (ESRD). Unfortunately, the 
number of renal registries in developing countries was not prominent in this review. In Iran, the transplant office in 
the Iranian Ministry of Health and Medical Education has taken the initiative to establish a transplant registry, which 
includes kidney transplantations. A comprehensive renal registry that also includes the early stages of CKD, 
however, has not so far been in place at neither national nor local levels. Therefore, to address this deficiency, a 
renal registry development project was started in the West Azerbaijan province in 2016. This article describes the 
initiatory yet crucial steps taken to establish such a registry at our healthcare context. As a fundamental step in 
designing any disease registry (10), we first and foremost aimed to define the objectives of founding a renal registry 
in our context, to identify opportunities, threats and challenges along the way, as well as to extract its essential 
minimum data set (MDS).  
2. Methods 
This was a mixed method study conducted in two phases: 1) a qualitative study using interviews and document 
analysis, and 2) a quantitative study using a modified Delphi survey. The details of these two, including the process 
to extract MDS for a CKD registry, are described below. The study started late fall 2016 and lasted till late summer 
2017. Before the start of the study, it was approved by the research ethics committee of UUMS. Formal written 
consent was not sought from the participants because acceptance of our invitation for an interview and also 
submission of completed questionnaires by the survey participants were taken as implied consent. Even so, before 
any data collection, we informed our participants about the confidentially of any information provided by them.  
2.1. Phase 1: qualitative study 
In this part of the study, we used interviews and document analysis. We interviewed 17 key experts with the 
knowledge of merits and pitfalls of CKD care in our context. As individuals with different types of knowledge, 
expertise and skills are involved in CKD care, we invited representatives of all key stakeholders i.e., physicians, 
nurses and data managers to participate in our study (please see the result section). Our interview participants were 
identified through a purposive sampling after interviewing their first group. During interviews, we focused on the 
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questions to define the objectives of such a registry in our healthcare context, and to identify opportunities and 
possible threats and challenges along the way. We were interested to analyze how these issues might affect 
establishing a given CKD registry. More than one interview was held with some of our participants but in different 
occasions. Interviews were in-depth, semi-structured, one-on-one and face-to-face. Interviews lasted 30-45 minutes 
each. After ensuring the confidentiality of information provided, 12 interviews were voice recorded and transcribed 
verbatim and analyzed before conducting a new one. During the other interviews, interview notes were concurrently 
taken and their contents were approved by the participants. This helped to organize the questions for the consequent 
interviews and to check the validity of our preliminary interpretations with the participants. The interviews were 
continued until data saturation was achieved. 
We analyzed our qualitative data using a “grounded theory” approach (15). In this method, data was coded around 
the areas of our research interests and aims until the main themes emerged. The overall data analysis for the present 
study was conducted by the first and the corresponding authors independently and the resulting themes were 
discussed in multiple meetings till consensus was reached.  
2.2. Phase 2: quantitative study using a modified Delphi survey 
We reviewed the literature and also the official websites of leading CKD registries already identified in (14), in both 
international and national levels of developed and developing countries, and extracted their common data elements 
whenever they were publicly available (for example please see (13, 16-24)). To cover all CKD stages, we were 
interested in all renal registries encompassing either earlier, later or entire CKD stages. To the list of extracted 
common data elements, we added the data items of interest for our main stakeholders or future users (i.e., 
nephrologists, nurses and care managers) especially those data items mentioned as essential for data management 
tasks. By incorporating these two sources, we developed the first version of a questionnaire. The questionnaire 
consisted of data items organized in 10 categories in English. In front of each item, it was documented which 
country’s renal registry included that item. Participants were asked to rate the necessity of inclusion of an item in the 
MDS using a three-point likert scales i.e., “very important=2”, “important=1” and “not important=0”.  
In order to select MDS, we used a modified Delphi survey defined as “Delphi rounds plus a physical meeting” (25). 
This method has already been used successfully to develop a MDS for clinical fields (26, 27). In round 1, we 
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distributed the questionnaire to 14 physicians, nurses and managers in nephrology care.  Following review of the 
first round’s responses, it was decided that two slightly different questionnaires would be distributed in the second 
round to target pediatrics and adult patient registrations individually. This was mainly because of the sake of greater 
clarity and some slightly differing information needs of our clinicians for pediatrics and adult patient populations. 
Round 2 of the Delphi was conducted through sending an email survey to key informants working in other medical 
universities and inviting them to rate the data elements. A sampling was not used for this purpose and the inclusion 
in this invitation was merely based on our familiarity with participants.  
2. 3. Data analysis 
In both rounds, percentages and mode values were used for outcome measures as indicators of agreement on the 
three-point scales. Decision to include an item was based on achieving consensus when greater than 60% of 
respondents rated that item as “very important=2” or “important=1” indicating a clear majority. If greater than 60 % 
of participants scored an item as “very important” with mode 2, that item was considered mandatory in our intended 
CKD registry. The remaining selected items, which commonly had mode 1, were considered voluntary. Comments 
provided by the respondents in the questionnaires were also analyzed thematically. Quantitative statistical analyses 
of the rating of data items were undertaken with the SPSS software version 16. Meetings were held with senior adult 
and pediatric nephrologists to discuss the results of analysis and to make decisions on the final data categories and 
items.   
3. Results 
3.1. Qualitative results 
In total, 26 interviews were conducted with 17 key experts who were 5 adult and 2 pediatrics nephrologists, 2 kidney 
transplant surgeons, 4 nephrology nurses in the nephrology and kidney transplant wards, 4 experts from Urmia 
University of Medical Sciences’ vice chancellor of clinical affairs and the charity organization for supporting 
patients with kidney disease. Table 1 provides details of these interviews. 
[Inset Table 1 here] 
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3.1.1. Objectives and expected benefits of a CKD registry 
The interviews revealed that all our interviewees commonly believed that developing and establishing a CKD 
registry would be a pivotal step to provide a qualitative, coordinated CKD care. We identified the following 
perceived goals that can be achieved by establishing a viable CKD registry. In the views of our participants, 
especially physicians, the most notable goal with a CKD registry would be collecting accurate data and information 
of CKD patients in different stages, particularly those in earlier stages before they develop into ESRD. The 
following quote spells the point out: 
“…In my opinion, the most important issue is that we first need to know the exact number of 
our CKD patients in the province and then think about designing and implementing 
interventions …. [after knowing the number] we need to think what we can do to stop [or slow 
down] the progress of their disease into ERSD with interventions such as medications, patient 
education or life style changes ….” (A senior nephrologist, 27th of November 2016) 
Having accurate data would provide physicians with the opportunity to track and monitor the progress of CKD 
patients more closely and actively in the early stages. They told us the tales of multiple patients who had been in 
earlier CKD stages but due to different reasons nephrologists had lost track of patients’ renal function trajectory and 
then these patients came back for follow-up visits in their final CKD stages. Our nephrologists expected that 
recalling such lost to follow up patients to receive evidence-based CKD care would be a much easier task by 
registering and actively chasing them. This way, clinicians might be able to prevent or at least to delay the rapid 
progression to ESRD saving hundreds of kidneys. In order to have a thorough overview on the CKD patients in our 
region, it was proposed that all patients would be targeted for registration regardless of their stages except when they 
do not give consent for registry or receive kidney transplantation.  
Our interviewees stated that having reliable data in such registry will have multiple benefits. It will facilitate 
organizing and also managing a more coordinated CKD care by informing the main stakeholders such as 
nephrologists, nephrology nurses, internal medicine specialists and family physicians, governmental and non-
governmental organizations as well as policy makers. It can also aid clinicians to control CKD complications such 
as cardiovascular diseases, anemia and metabolic bone disorders before they become urgent or irreversible. Next, 
conducting research on epidemiology or the clinical aspects of CKD care in our setting will be promoted. On that 
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account, the main CKD causes and also contributing factors on its progression trajectory can be better known. Last 
but not least, such information would inform policy makers’ decisions regarding health system planning and 
capacity building for CKD care as one of our interviewees remarked on this issue:    
“…the financial data we receive are accurate because we have their official documents; but 
about the other [patients’ non-financial, clinical] data, they are often incomplete because we 
do not have the necessary infrastructure for reliable data collection, although some are 
collected on line… Because our planning is based on the data which is sent to us, therefore the 
[clinical] recorded data is very important for us.” (A registry manager, 20th of December, 
2016) 
3.1.2. Challenges and opportunities 
Our results also showed that although a CKD registry was considered instrumental in achieving the above 
mentioned goals and benefits, our participants were deeply concerned about a number of challenges that may 
undermine the efforts for the registry establishment or threaten its success and maintenance. The most frequently 
mentioned challenge in our study was the shortages of financial and human resources to cover up required workload. 
As emerged, it seemed a prerequisite to recruit designated individuals with information technology knowledge to 
collect necessary data from various sources and then populate the registry with those data. If data entry tasks are to 
be assigned to clinicians, then their motivations for cooperation should properly be addressed. For example, it was 
suggested that financial or other ways of compensations for this increased workload could be considered such as 
decreased shift work. It should also be noted that in addition to the nephrologists and nurses in academic hospitals 
and clinics, other clinicians such as internal medicine specialists or even family physicians are currently involved in 
providing CKD care in the community. In order to have their contribution in a given CKD registry, attractive 
secondary benefits either financial or non-financial might be compelling.  
Moreover, in order to lessen data entry workload and make it a pleasing experience, it was advised that the data 
items and the efforts required for their entry should be kept as minimal as possible, particularly in early 
implementation stages. Next challenge highlighted by our participants was a fragile infrastructure to deploy the 
information and communication technology across the province for sharing data through a registry. In their views, a 
comprehensive single source of patient data is greatly lacking in the current healthcare system. Therefore, the data 
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must be compiled from multiple sources and then should be validated by qualified individuals to be credible for 
clinical decisions and policy making purposes.  
Alongside the above mentioned challenges, the following opportunities were also identified in the way of 
establishing a CKD registry for our setting: 1) ownership of the project by clinician leaders i.e., medical 
informaticians, nephrologists and transplant surgeons, 2) the focus and emphasis on collecting clinically relevant, 
rather than financial and administrative, data items aiming to promote a sustainable, qualitative CKD care, and 3) 
project alignment with the university’s top research priorities and recent initiatives such as a large CKD screening 
project newly funded by the National Institute for Medical Research Development (NIMAD) of Iran. 
3.2. Quantitative results 
In total, 18 local and national experts in nephrology care participated in the Delphi survey. In the first round, from 
14 invited participants, all completed the questionnaire (100% response rate). Eleven did so in the second round 
from which 4 were new participants all invited from other academic centers across the country (i.e., Tehran, Shiraz 
and Kermanshah universities of medical sciences). The majority of the survey participants were physicians (60%) 
and men (56%). All were experienced and key experts in their professions or managerial roles. 
3.2.1. Data elements 
The final validated data elements in our study were composed of 168 elements in 11 categories. These categories 
were consisted of demographics (16 elements), history of patient’s CKD (11 elements), patient’s other clinical 
histories (16 elements), patient family history (4 elements), current visits (17 elements), dialysis (34 elements), 
laboratory tests (46 elements), medications (17 elements), vaccinations (2 elements), ultrasonography results (3 
elements) and mortality data (2 elements). Table 2 provides details of these data elements, their percentages and 
modes.  
[Insert Table 2 here] 
4. Discussion 
In this study, we aimed to characterize the main objectives of founding a CKD registry in our healthcare context. 
Our participants’ leading interest in establishing a registry was centered on providing a qualitative and coordinated 
care for their CKD patients, particularly those in earlier stages. They assumed that collecting and collating reliable 
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information of CKD patients would enable conducting research and planning tailored prevention and management 
strategies in order to appropriately target in need patients. Using the Delphi survey, we defined a MDS to develop 
such a registry. The resulting MDS was more clinically oriented mainly because our participants put the quality of 
care at the center stage.  
Despite the higher incidence and prevalence in earlier CKD stages, the majority of renal registries capture data of 
ESRD patients undergoing renal replacement therapy (RRT) (14). The United States Renal Data System (USRDS) 
for ESRD patients has been operational since 1989 (28). Till rather recently, however, this country lacked a 
comprehensive surveillance program to capture and track all aspects of CKD especially for those not yet receiving 
renal replacement therapy. Therefore, a CKD surveillance system was established to encompass all CKD stages 
aiming towards primary prevention, earlier detection and implementation of optimal disease management strategies 
in 2010 (29). So far, very few registries have aimed to collect data on earlier CKD stages. In Australia, to address 
the data gap on earlier CKD stages, a surveillance program including a registry was established to include all public 
health renal practices across the province of Queensland (30). To collect data of all CKD patients, the Indian Society 
of Nephrology embarked on developing a CKD registry as a nationwide data warehouse (23). The Serbian pediatric 
CKD registry also included CKD stages 2-5 (24). Similarly, in our study, registry aims were set to embrace all CKD 
stages of both adults and children patients with particular emphasis to capture events and monitor trends for patients 
in earlier stages enabling better care planning and policy makings for future.  
It has been noted that the priorities of stakeholders are key for a renal registry to succeed (10, 31). Outlining 
objectives with main stakeholders’ full engagement is extremely important to fulfill their information needs, 
soundly. Following this approach, we defined a MDS that most commonly focused on capturing items that are of 
paramount importance from quality of care perspectives. Unavoidably, there are likely different perspectives among 
researchers and clinicians in other settings. For example, in some renal registries, it is necessary to capture financial 
data (see for instance (20, 32)). In our qualitative study, the participants expressed their unwillingness for such data 
items to populate this registry. Because we put our clinicians’ needs at the center stage, it is possible that our 
primary MDS used to initiate the registry is not comprehensive enough to address all the questions of researchers 
with broad research interests. Yet, such registries provide the basic information necessary to identify and recruit a 
representative research samples, as the experience of UK renal registry also shows (33).  
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To gain success, MDS in patient registries should be flexible enough to incorporate new data elements based on 
evolving needs of clinicians and researchers (31). For example, since conception of Korean renal registry in 1985, it 
has been evolving to include more and more clinically relevant data items, such as dialysis adequacy and lab data 
(34). This was the case in USRDS as well, in which other objectives such as conducting economic and biomedical 
research were added later on in 1994 (35). We may also need to go through data revisions to capture additional 
information or to clean away superfluous data items after primary implementation phase. Fortunately, the in-house 
development of this registry makes its tailoring according to evolving needs more feasible. Moreover, in several 
renal registries, MDS of kidney transplantations were incorporated within ESRD registries (18-21). Nevertheless, 
we did not consider any MDS for kidney transplant in our study. This was mainly because of an already existing 
registry for transplantations in Iran. Therefore, we decided to avoid redundant or duplicate workload for our 
clinicians. It would be more productive if such registries with complementary aims could be linked to share data in 
future.   
Information technology including registry systems has multiple benefits especially for chronic diseases (36, 37). 
Chronic care such as care delivered to CKD patients is highly collaborative. New models of care are needed for 
improved CKD care (38). A renal registry can play an important role in the implementations of chronic care models 
for CKD (39). Moreover, renal registries can facilitate establishing national CKD surveillance systems, as shown by 
successful initiatives in developed countries (29, 30, 40). In a study of clinicians’ attitudes towards a CKD registry 
in the United Sates, they believed that it has the potential to support their practice by identifying patients fallen out 
of care, recognizing CKD progression, tracking quality metrics and abnormal lab values, and providing evidence 
based decision supports (41). Our participants had similar attitudes towards the potential benefits of a CKD registry. 
Yet, they highlighted the workload of data collection and the required financial, technical and human recourses as 
potent inhibitors of a successful implementation if not considered and secured beforehand. These issues have played 
an important role in failure of a number of renal registries in developing countries (17). We too should carefully 
consider the identified challenges and threads when we embark on full implementation and maintenance of such a 
registry in our healthcare context. It should be noted that, in the light of successful experiences of implementing 
national registries such as cancer and trauma in Iran, the prospect to secure the required resources from the Iranian 
ministry of Health is promising for CKD registry implementation.      
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4. 1. Limitations 
While we believe that our study is the first practical initiative to establish a CKD registry in our health care context, 
we recognize there were limitations. First, this research was conducted at provincial health care level. Therefore, 
further studies are needed for findings to be generalizable to the whole country. Although we believe the list of 
MDS identified in our study is inclusive and relevant from the quality of care perspectives, this data set may need to 
be vetted by a larger group of clinicians to be applicable nationwide. Further, we used the Delphi survey to reach a 
consensus on the data items. This method has been shown to be a useful method to define the objectives of such 
systems, their associated measures and data items (29). However, one of its limitations is that minority opinions are 
marginalized. Finally, it is possible that important items were overlooked or not considered in our study. After initial 
implementation, we remain open to necessary modifications by collecting and collating suggestions for future 
possible MDS revisions. 
5. Conclusion 
We reported the initiatory steps taken to establish a CKD registry in an Iranian healthcare context. We focused on 
the information needs and priorities of our main stakeholders in order to define the objectives of establishing a CKD 
registry in Iran and its MDS. Our results showed that the quality of care perspectives influenced both the registry 
objectives and its MDS. Although, the required workload for clinicians was identified as the main challenge in this 
study, collecting minimally needed data longitudinally may benefit clinicians by addressing their main information 
needs about their patients. We hope this approach will facilitate its endorsement. Noteworthy that, following the 
current study, we developed a renal registry system that, by the time of this report, was in pilot phase at an academic 
renal center affiliated to Urmia University of Medical Sciences. We hope that the insights gained in this study will 
advance the efforts of our clinicians, researchers and policy makers for a qualitative CKD care. 
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Table 1. Details of interviews with study participants 
Professions and roles Number of interviews held 
Adult nephrologists 7 
Pediatrics nephrologists 5 
Kidney transplant surgeons 2 
Adult and pediatrics nephrology and transplant nurses 8 
Managerial key informants in the vice chancellor of clinical affairs  2 
Managerial key informants in the society of kidney patient support charity 2 
 
Table 2. Minimum CKD data set identified in our study for designing a CKD registry 
Category Data Items (% with mode) 
16 
 
Demographic information (16) 
 100% with mode 2: First and last names, date of birth, national 
identification number, gender, height and weight (for BMI), 
blood group, socioeconomic status, place of residence (city and 
province), contact number (fixed and mobile), type of insurance  
 90.9% with mode 2: level of education 
 81.4% with mode 2: provider name (hospital or care center ) 
History of patient’s CKD (11) 
 100% with mode 2: The main cause of CKD and the history of 
other kidney related symptoms or diseases;  pathologic report of 
kidney biopsy; history of nephrotoxic drug use; age and serum 
creatinine level when first diagnosis made;  date of first visit by a 
nephrologist; the Renal Replacement Therapy (RRT) method 
used for the first time; date of the first RRT; history of renal TX 
 90.9% with mode 2: CKD stage when first diagnosis made 
Patient’s other clinical histories (16) 
 100% with mode 2: Diabetes mellitus (including diabetic 
nephropathy), cardiovascular diseases (including history of 
angioplasty and vascular graft), history of hyperlipidemia, 
hematological disorders, thyroid disorders, bone disorders, 
cancer, congenital diseases, metabolic diseases, pre-dialysis 
immunosuppression use (more than 3 months per 12 months),  
 100% with mode 1: chronic lung diseases 
 90.9% with mode 2: psychiatric disorders, infectious diseases 
(including hepatitis, CMV and HIV), smoking and alcohol use 
 90.9% with mode 1: drug allergies 
Patient family history (4) 
 100% with mode 2: History of any kidney disease in the first 
degree family member (including hematuria), diabetes, 
hypertension, cardiovascular diseases  
Current visits (17)  100% with mode 2: visit date, systolic and diastolic blood 
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pressure values, heart rate, Ultra filtration ( in 24 hours), height 
and weight (for BMI), edema status, features of uremia (e.g., 
cardiovascular complications, acid-base or electrolyte 
complications, central or peripheral nervous system 
manifestations, etc.), hyperlipidemia status, hematological 
disorders, current RRT method; age and serum creatinine level  
whenever a change in the patient’s CKD stage is occurred 
(including at ESRD)  
 100% with mode 1: heart rate and thyroid disorders 
 90.9% with mode 2: current CKD stage 
Dialysis 
(34) 
Hemodialysis (7) 
 100% with mode 2: vascular access, frequency of dialysis per 
week, type of dialysis solution, urea reduction ratio % 
 90.9% with mode 2: blood flow rate 
 81.8% with mode 2: type of dialysis filter and KT/V 
Peritoneal 
dialysis 
(27) 
Peritoneal 
catheterization 
(8) 
 100% with mode 2: type of catheter, catheterization method, 
duration of catheterization, omentectomy report, catheter 
functioning status inside the operating room, any complications 
occurred during and after catheterization 
  100% with mode 1: exit site quadrants 
Dialysis 
session (12) 
 100% with mode 2: Type of dialysis solution, volume of the 
solution, symptoms at the onset of dialysis, duration of dialysis 
session, the frequency of dialysis per week, the cause of any 
dialysis failure, the patient's RRT or state whenever peritoneal 
dialysis is stopped (such as full recovery, HD, TX, etc.,) 
 66.7% with mode 2: the compounds used in the dialysis fluid, 
time to leave the solution in the peritoneum, the number of cycles 
per day, serum potassium pre-dialysis, serum potassium post-
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dialysis 
Peritonitis 
cases (7) 
 100% with mode 2: Peritoneal fluid analysis, treatment of 
peritonitis (i.e., antibiotics used, duration of treatment, change of 
an antibiotic), final result of peritonitis treatment   
 66.7% with mode 2: peritoneal fluid culture and antibiogram test 
Laboratory tests (46) 
 100% with mode 2: Complete blood count (WBC with diff, RBC, 
Hg, Platelet), Creatinine, Creatinine clearance, Bicarbonate, 
Potassium, Sodium, Urea, Calcium, Phosphate, FBS, Hg A1c (for 
diabetic patients), CRP, Iron, TIBC, Ferritin, Liver function tests 
(i.e., ALP, ALT, AST, Albumin, Bilirubin), iPTH, Thyroid 
function tests (i.e., TSH, T4, T3), Hepatitis B, Urine full report 
(including RBC, WBC, protein, glucose, ketone and bacteria), 
Urine volume (in 24 hours), Urine protein test (in 24 hour urine), 
CMV test, Venereal disease research laboratory (VDRL) test   
 Between 62.5% and 90.9% with mode 2: Urea clearance, ESR, 
Lipid profile (i.e., Triglycerides, HDL, LDL, total Cholesterol), 
Hepatitis C, Toxoplasmosis test 
Medications (17) 
 100% with mode 2: Antihypertensive agents, Anti- 
hyperlipidemic agents, Anti-diabetic agents (including Insulin), 
Erythropoietin agents, Iron supplements, Folic acid, Vitamin D3, 
Calcium, Phosphate binders, Sodium bicarbonate, Growth 
hormone (for pediatrics), Antihistamines, Opioid analgesics, and 
details of a medication (name, unit, frequency, dosage, route)  
 87.5 with mode 2: Allopurinol, Laxatives, 
 90% (45% with mode 2 and 45% with mode 1): Anticoagulants, 
Vaccination (2) 
 100% with mode 2: Vaccination type and date (including 
Hepatitis vaccine, Pneumococcal vaccine, Influenza vaccine, 
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Meningitis and Tetanus vaccines (only for pediatrics))  
Ultrasonography results (3) 
 100% with mode 2: Abdominal (including urinary tract), Neck  
 90% (45% with mode 2 and 45% with mode 1): Pelvic 
Death data (2)  100% with mode 2: Date of death, the main cause of death 
 
Abbreviations: Chronic Kidney Disease (CKD), End Stage Renal Disease ( ESRD), Body Mass Index (BMI), Renal 
Replacement Therapy (RRT), Kidney transplantation (TX), Hemodialysis (HD), Cytomegalovirus (CMV), Human 
Immunodeficiency Virus (HIV), White Blood Cells (WBC), Red Blood Cells (RBC), Hemoglobin (Hg), Fasting 
Blood Sugar (FBS), Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP), Total Iron Binding Capacity 
(TIBC), High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), Alkaline Phosphatase (ALP), Alanine 
Aminotransferase (ALT), Aspartate Aminotransferase (AST), Intact Parathyroid Hormone (iPTH), Venereal disease 
research laboratory (VDRL), KT/V: a number used to quantify dialysis treatment adequacy) 
 
Highlights 
 Disease registries provide reliable data planning and policymaking of chronic care  
 Registry data particularly on earlier CKD stages is crucial for informed policy making 
 Securing adequate financial, technical and human resources is a challenge for registries 
 In a developing setting, a clinician supported registry MDS can ease its initial implementation  
 
 
